This Article Full Text (PDF) All Versions of this Article: 0272989X08317015v1 28/6/926    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Khanna, D. Articles by Eckman, M. H. Search for Related Content PubMed PubMed Citation Articles by Khanna, D. Articles by Eckman, M. H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CYCLOPHOSPHAMIDE Medline Plus Health Information Scleroderma Social Bookmarking                   What's this?

Oral Cyclophosphamide for Active Scleroderma Lung Disease: A Decision Analysis

Division of Rheumatology, School of Public Health, University of California at Los Angeles, dkhanna{at}mednet.ucla.edu, Department of Health Services, School of Public Health, University of California at Los Angeles

Daniel E. Furst, MD

Division of Rheumatology, University of California at Los Angeles

Philip J. Clements, MD, MPH

Division of Rheumatology, School of Public Health, University of California at Los Angeles

Donald P. Tashkin, MD

Pulmonary Medicine and Critical Care Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles

Mark H. Eckman, MD

Division of General Internal Medicine, Department of Medicine, University of Cincinnati, Cincinnati, Ohio, Institute for the Study of Health, University of Cincinnati, Cincinnati, Ohio

Background. Results from the recent Scleroderma Lung Study (SLS) show that oral cyclophosphamide (CYC) is better than placebo in preventing the progression of scleroderma-related interstitial lung disease (SSc-ILD) at 12 mo but is associated with adverse events. Also, the long-term balance of risk and benefit remains unclear. Methods. The authors evaluate the risk-benefit tradeoffs using a Markov decision analytic model to project the quality-adjusted life years (QALYs) for strategies of CYC versus no CYC in SSc-ILD. The base case examined a 50-y-old woman with SSc of 1.5 y, SSc-ILD with moderate ventilatory restriction. The authors analyze the decision to treat with 1 y of daily CYC versus no SSc-ILD—specific therapy. Based on 2-y data from the SLS, the authors assume CYC resulted in no survival benefit and only a transient beneficial impact on pulmonary function. They explore the impact of changes in model parameters through sensitivity analyses, including the efficacy of CYC in preventing progression of lung disease and SSc-ILD— related death. Results. In the base-case analysis, CYC-treated patients fared worse, with a small loss of 0.21 QALYs (16.84 v. 17.15). CYC remained inferior across sensitivity analyses for most variables. In analyses assuming a survival benefit with CYC, CYC resulted in a clinically significant gain (18.17 v. 17.15 QALYs). Conclusions. CYC therapy for 1 y results in a small loss in QALYs compared with no CYC for SSc-ILD. The lack of a beneficial impact on survival and the transience of CYC's impact on decline in pulmonary function drive this conclusion.

Key Words: Scleroderma Lung Study • scleroderma • cyclophosphamide • interstitial lung disease • pulmonary fibrosis • decision analysis.

This version was published on November 1, 2008

Medical Decision Making, Vol. 28, No. 6, 926-937 (2008)
DOI: 10.1177/0272989X08317015


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Behr and V. J. Thannickal Update in Diffuse Parenchymal Lung Disease 2008 Am. J. Respir. Crit. Care Med., March 15, 2009; 179(6): 439 - 444. [Full Text] [PDF]